Analysts cut their consensus target price for PAYX by nearly 3% this week. The payroll services giant now has a consensus target of $113.93, down from $117.29. The stock has lost 9.4% year-to-date. Its RSI sits at a deeply oversold 22, suggesting the selloff may be overdone.
With a 5.1% forward dividend yield, income investors may find the dip attractive. The analyst community remains split. Two sell ratings weigh against two buys, with 15 holds in the middle.
Charles River Laboratories saw a quieter but meaningful shift. One analyst removed a recommendation, leaving the consensus leaning heavily toward sells — 13 of 16 analysts are negative on the name. The average target dropped to $298.79 from $289.29. Yet the stock is up 47.6% year-to-date. That gap between analyst caution and price performance is striking.
Elsewhere, a wave of recommendation removals hit the EDA software space. Both SNPS and CDNS lost a buy rating each. Both stocks carry near-unanimous buy consensus from remaining analysts, with average targets of $554 and $405 respectively.
Marsh & McLennan also lost a recommendation. The insurance broker trades at an $81bn market cap. Its SI % FF is just 1.2%, signalling very little short-seller interest.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
